Skip to main content

Table 1 Patients’ characteristics

From: Efficacy and safety-in analysis of short-course radiation followed by mFOLFOX-6 plus avelumab for locally advanced rectal adenocarcinoma

Demographics, n

13

Median age, years (range)

62.2 (33.7–74.0)

Sex, n (%)

 Male

9 (69.2)

 Female

4 (30.8)

Nationality, n (%)

 Lebanese

8 (61.5)

 Iraqi

2 (15.4)

 Jordanian

3 (23.1)

ECOG performance status, n (%)

  ≤ 1

13 (100)

  > 1

0 (0)

MMR mutational status, n (%)

 MSS

13 (100)

 MSI-H

0 (0)

Tumor histology type, n (%)

 Intestinal

10 (76.9)

 Mucinous

1 (7.7)

 Combined Mucinous and Intestinal

1 (7.7)

 Combined Signet ring cell and Intestinal

1 (7.7)

Tumor differentiation, n (%)

 Well

2 (15.3)

 Moderate

10 (77)

 Poorly

1 (7.7)

Median distance from anal verge, cm (range)

10 (3–14)

Clinical stage, n (%)

 TxN1

1 (7.7)

 T3N0

1 (7.7)

 T3N1

4 (30.8)

 T3N2

7 (53.8%)

  1. ECOG, Eastern Cooperative Group Oncology Status; MMR, mismatch repair; MSI-H, microsatellite instability-high; MSS, microsatellite-stable